Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study)

References

• Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–10. doi:10.1001/jama.2016.0287.
   PubMed Web of Science ®Google Scholar
• Dugani S, Kissoon N. Global advocacy needed for sepsis in children. J Infect. 2017;74(Suppl 1):S61–S65. doi:10.1016/S0163-4453(17)30193-7.
   PubMedGoogle Scholar
• Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, Singhi SC, Erickson S, Roy JA, Bush JL, et al. Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) network. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147–57. doi:10.1164/rccm.201412-2323OC.
   PubMed Web of Science ®Google Scholar
• Kawasaki T. Update on pediatric sepsis: a review. J Intensive Care 2017;5:47. doi:10.1186/s40560-017-0240-1.
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–E30. doi:10.1111/1469-0691.12070.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657–63. doi:10.1093/jac/dkq494.
   PubMed Web of Science ®Google Scholar
• Morin L, Kneyber M, Jansen NJG, Peters MJ, Javouhey E, Nadel S, Maclaren G, Schlapbach LJ, Tissieres P. ESPNIC refractory septic shock definition taskforce and the infection, systemic inflammation and sepsis ESPNIC section. Translational gap in pediatric septic shock management: an ESPNIC perspective. Ann Intensive Care. 2019;9(1):73. doi:10.1186/s13613-019-0545-4.
   PubMedGoogle Scholar
• Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77. doi:10.1007/s00134-017-4683-6.
   PubMed Web of Science ®Google Scholar
• Vianna RC, Gomes RN, Bozza FA, Amâncio RT, Bozza PT, David CM, Castro-Faria-Neto HC. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004;21(2):115–20. doi:10.1097/01.shk.0000111828.07309.26.
   PubMed Web of Science ®Google Scholar
• Marshall JC. Endotoxin in the pathogenesis of sepsis. Contrib Nephrol. 2010;167:1–13. doi:10.1159/000315914.
   PubMed Web of Science ®Google Scholar
• Podd BS, Simon DW, Lopez S, Nowalk A, Aneja R, Carcillo JA. Rationale for adjunctive therapies for pediatric sepsis induced multiple organ failure. Pediatr Clin North Am. 2017;64(5):1071–88. doi:10.1016/j.pcl.2017.06.007.
   PubMed Web of Science ®Google Scholar
• Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677–85.
   PubMed Web of Science ®Google Scholar
• Kakoullis L, Pantzaris ND, Platanaki C, Lagadinou M, Papachristodoulou E, Velissaris D. The use of IgM-enriched immunoglobulin in adult patients with sepsis. J Crit Care 2018;47:30–35. doi:10.1016/j.jcrc.2018.06.005.
   PubMed Web of Science ®Google Scholar
• Cui J, Wei X, Lv H, Li Y, Li P, Chen Z, Liu G. The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care 2019;9(1):27. doi:10.1186/s13613-019-0501-3.
   PubMedGoogle Scholar
• Aukrust P, Frøland SS, Liabakk NB, Müller F, Nordøy I, Haug C, Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84(7):2136–43. doi:10.1182/blood.V84.7.2136.2136.
   PubMed Web of Science ®Google Scholar
• Rieben R, Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999;93(3):942–51. doi:10.1182/blood.V93.3.942.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–68. doi:10.1016/S1473-3099(13)70001.
   PubMed Web of Science ®Google Scholar
• Schlapbach LJ, Straney L, Alexander J, MacLaren G, Festa M, Schibler A, Slater A. ANZICS Paediatric Study Group. Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002–13: a multicentre retrospective cohort study. Lancet Infect Dis. 2015;15(1):46–54. doi:10.1016/S1473-3099(14)71003-5.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Apostolidou E, Lada M, Perdios I, Gatselis NK, Tsangaris I, Georgitsi M, Bristianou M, Kanni T, Sereti K, et al. Hellenic Sepsis Study Group. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care 2013;17(5):R247. doi:10.1186/cc13073.
   PubMed Web of Science ®Google Scholar
• Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, Andaluz-Ojeda D, Muriel-Bombín A, Merino P, García-García MM, Citores R, Gandía F, Almansa R, et al. GRECIA Group (Grupo de Estudios y Análisis en Cuidados Intensivos). Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med. 2014;276(4):404–12. doi:10.1111/joim.12265.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Corcione S, Tascini C, Pasero D, Rocchetti A, Massaia M, Berlot G, Solidoro P, Girardis M. A position paper on IgM-enriched intravenous immunoglobulin adjunctive therapy in severe acute bacterial infections: the TO-PIRO SCORE proposal. New Microbiol. 2019;42(3):176–80.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Tziolos N, Routsi C, Katsenos C, Tsangaris I, Pneumatikos I, Vlachogiannis G, Theodorou V, Prekates A, Antypa E, et al. Hellenic Sepsis Study Group. Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clin Microbiol Infect. 2016;22(6):499–506. doi:10.1016/j.cmi.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Capasso L, Raimondi F. Promoting unbiased science on IgM-enriched immunoglobulins. Clin Microbiol Infect. 2017;23(1):55. doi:10.1016/j.cmi.2016.09.014.
   PubMed Web of Science ®Google Scholar
• Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;(9)CD001090. doi:10.1002/14651858.CD001090.pub2.
   PubMed Web of Science ®Google Scholar
• Cavazzuti I, Serafini G, Busani S, Rinaldi L, Biagioni E, Buoncristiano M, Girardis M. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med. 2014;40(12):1888–96. doi:10.1007/s00134-014-3474-6.
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005;23(4):298–304. doi:10.1097/01.shk.0000157302.69125.f8.
   PubMed Web of Science ®Google Scholar
• Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, Vincent JL, Werdan K, Martin-Loeches I, Almirall J, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44(4):438–48. doi:10.1007/s00134-018-5143-7.
   PubMed Web of Science ®Google Scholar
• Popov D, Yaroustovsky M, Lobacheva G. Prevention of infectious complications after heart surgery in children: procalcitonin-guided strategy. Kardiochir Torakochirurgia Pol. 2014;11(2):140–44. doi:10.5114/kitp.2014.43840.
   PubMedGoogle Scholar
• Kola E, Çelaj E, Bakalli I, Lluka R, Kuli-Lito G, Sallabanda S. Efficacy of an IgM preparation in the treatment of patients with sepsis: a double-blind randomized clinical trial in a pediatric intensive care unit (Original research). SEEJPH. 2014 Feb 9. doi:10.12908/SEEJPH-2014-04.
   Google Scholar
• El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005;51(5):271–78. doi:10.1093/tropej/fmi011.
   PubMed Web of Science ®Google Scholar
• Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, Tartamella F, Prisco L, Bigotto F, Bigolin T, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care 2012;27(2):167–71. doi:10.1016/j.jcrc.2011.05.012.
   PubMed Web of Science ®Google Scholar